Literature DB >> 27126628

B-cell signaling in persistent polyclonal B lymphocytosis (PPBL).

Nadine Voelxen1, Claudia Wehr1,2, Sylvia Gutenberger1, Baerbel Keller1, Miriam Erlacher3, Cecilia Dominguez-Conde4, Daniela Bertele3, Florian Emmerich5, Milena Pantic2, Stefanie Jennings1, Mirzokhid Rakhmanov1, Christian Foerster1, Uwe M Martens6, Uwe Platzbecker7, Hans-Hartmut Peter1, Paul Fisch8, Kaan Boztug4,9, Hermann Eibel1, Ulrich Salzer1, Klaus Warnatz1.   

Abstract

Persistent polyclonal B lymphocytosis (PPBL) is a benign hematological disorder characterized by a selective expansion of circulating polyclonal marginal zone (MZ)-like B cells. Previous reports demonstrated that cases of PPBL showed poor activation, proliferation and survival of B cells in vitro, yet the underlying defect remains unknown. Here we report for the first time an attenuated activation of the canonical NF-κB (nuclear factor of kappa light polypeptide gene enhancer in B cells) and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway after CD40 stimulation. This defect was selective, as alternative NF-κB signaling after CD40 stimulation and both B-cell receptor- and Toll-like receptor 9-mediated activation remained unaffected. Reduced canonical NF-κB activation resulted in decreased IκBα and CD40 expression in resting cells. In PPBL patients, expression of Bcl-xL in MZ-like B cells did not increase upon activation, consistent with the high apoptosis rates of PPBL-derived B cells that were observed in vitro. The B-cell phenotype of mice with selective knockouts of early components of the CD40 signaling pathway resembles PPBL, but sequencing corresponding genes in sorted MZ-like B cells of PPBL patients did not reveal relevant genetic alterations. Nevertheless, the frequently observed mutations in early signaling components of the NF-κB pathway in MZ lymphomas underline the relevance of our findings for the pathogenesis of PPBL.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27126628     DOI: 10.1038/icb.2016.46

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  39 in total

1.  Chromosomal instability and ATR amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL).

Authors:  H Mossafa; S Tapia; G Flandrin; X Troussard
Journal:  Leuk Lymphoma       Date:  2004-07

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 3.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.

Authors:  Davide Rossi; Silvia Deaglio; David Dominguez-Sola; Silvia Rasi; Tiziana Vaisitti; Claudio Agostinelli; Valeria Spina; Alessio Bruscaggin; Sara Monti; Michaela Cerri; Stefania Cresta; Marco Fangazio; Luca Arcaini; Marco Lucioni; Roberto Marasca; Catherine Thieblemont; Daniela Capello; Fabio Facchetti; Ivo Kwee; Stefano A Pileri; Robin Foà; Francesco Bertoni; Riccardo Dalla-Favera; Laura Pasqualucci; Gianluca Gaidano
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 5.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

6.  All patients with persistent polyclonal B cell lymphocytosis present Bcl-2/Ig gene rearrangements.

Authors:  R Delage; J Roy; L Jacques; A Darveau
Journal:  Leuk Lymphoma       Date:  1998-11

7.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

8.  Polyclonal B-cell lymphocytosis with binucleated lymphocytes (PPBL).

Authors:  Xavier Troussard; Edouard Cornet; Jean-François Lesesve; Carine Kourel; Hossein Mossafa
Journal:  Onco Targets Ther       Date:  2008-10-01       Impact factor: 4.147

9.  Persistent Polyclonal B Cell Lymphocytosis B Cells Can Be Activated through CD40-CD154 Interaction.

Authors:  Emmanuelle Dugas-Bourdages; Sonia Néron; Annie Roy; André Darveau; Robert Delage
Journal:  Adv Hematol       Date:  2014-12-14

10.  Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.

Authors:  Andrew L Snow; Wenming Xiao; Jeffrey R Stinson; Wei Lu; Benjamin Chaigne-Delalande; Lixin Zheng; Stefania Pittaluga; Helen F Matthews; Roland Schmitz; Sameer Jhavar; Stefan Kuchen; Lela Kardava; Wei Wang; Ian T Lamborn; Huie Jing; Mark Raffeld; Susan Moir; Thomas A Fleisher; Louis M Staudt; Helen C Su; Michael J Lenardo
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307

View more
  2 in total

1.  Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure.

Authors:  Stefanie Kreutmair; Miriam Erlacher; Geoffroy Andrieux; Rouzanna Istvanffy; Alina Mueller-Rudorf; Melissa Zwick; Tamina Rückert; Milena Pantic; Teresa Poggio; Khalid Shoumariyeh; Tony A Mueller; Hiroyuki Kawaguchi; Marie Follo; Cathrin Klingeberg; Marcin Wlodarski; Irith Baumann; Dietmar Pfeifer; Michal Kulinski; Martina Rudelius; Simone Lemeer; Bernhard Kuster; Christine Dierks; Christian Peschel; Nina Cabezas-Wallscheid; Jesus Duque-Afonso; Robert Zeiser; Michael L Cleary; Detlev Schindler; Annette Schmitt-Graeff; Melanie Boerries; Charlotte M Niemeyer; Robert Aj Oostendorp; Justus Duyster; Anna Lena Illert
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Polyclonal B-cell lymphocytosis in English bulldogs.

Authors:  Emily D Rout; A Russell Moore; Robert C Burnett; Julia D Labadie; Kelly L Hughes; Paul A Navin; Janna A Yoshimoto; Paul R Avery; Anne C Avery
Journal:  J Vet Intern Med       Date:  2020-10-15       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.